Johnson, Bruce E.
Dana-Farber Cancer Institute
35 papers on CoChatORCID 0000-0002-5252-3677
Most cited papers
- Verified
Multimodal pooled Perturb-CITE-seq screens in patient models define mechanisms of cancer immune evasion
Frangieh, C. J., Melms, J. C., Thakore, P. I., Geiger-Schuller, K. R., Ho, P., Luoma, A. M., Cleary, B., Jerby-Arnon, L., Malu, S., Cuoco, M. S., et al. (2021) · Nature Genetics
Cancer Immunotherapy and BiomarkersSingle-cell and spatial transcriptomics
Cited by 276
- Verified
Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib
Jackman, D. M., Holmes, A. J., Lindeman, N., Wen, P. Y., Kesari, S., Borras, A. M., Bailey, C., de Jong, F., Jänne, P. A., & Johnson, B. E. (2006) · Journal of Clinical Oncology
Lung Cancer Treatments and MutationsColorectal and Anal Carcinomas
Cited by 260
- Verified
A rapid and sensitive enzymatic method for epidermal growth factor receptor mutation screening
Jänne, P. A., Borras, A. M., Kuang, Y., Rogers, A. M., Joshi, V. A., Liyanage, H., Lindeman, N., Lee, J. C., Halmos, B., Maher, E. A., et al. (2006) · Clinical Cancer Research
Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research
Cited by 214
- Verified
The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations—The Lung Cancer Mutation Consortium (LCMC2)
Aisner, D. L., Sholl, L. M., Berry, L. D., Rossi, M. R., Chen, H., Fujimoto, J., Moreira, A. L., Ramalingam, S. S., Villaruz, L. C., Otterson, G. A., et al. (2018) · Clinical Cancer Research
Lung Cancer Treatments and MutationsCancer Genomics and Diagnostics
Cited by 206
- Verified
The Impact of Initial Gefitinib or Erlotinib versus Chemotherapy on Central Nervous System Progression in Advanced Non–Small Cell Lung Cancer with EGFR Mutations
Heon, S., Yeap, B. Y., Lindeman, N. I., Joshi, V. A., Butaney, M., Britt, G. J., Costa, D. B., Rabin, M. S., Jackman, D. M., & Johnson, B. E. (2012) · Clinical Cancer Research
Lung Cancer Treatments and MutationsBrain Metastases and Treatment
Cited by 176
- Verified
Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors
Jänne, P. A., & Johnson, B. E. (2006) · Clinical Cancer Research
Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research
Cited by 147
- Verified
Neoadjuvant atezolizumab in resectable non-small cell lung cancer (NSCLC): Interim analysis and biomarker data from a multicenter study (LCMC3).
Kwiatkowski, D. J., Rusch, V. W., Chaft, J. E., Johnson, B. E., Nicholas, A., Wistuba, I. I., Merritt, R., Lee, J. M., Bunn, P. A., Tang, Y., et al. (2019) · Journal of Clinical Oncology
Cancer Immunotherapy and BiomarkersLung Cancer Diagnosis and Treatment
Cited by 146
- Verified
Impact of BRAF Mutation Class on Disease Characteristics and Clinical Outcomes in BRAF-mutant Lung Cancer
Dagogo-Jack, I., Martinez, P., Yeap, B. Y., Ambrogio, C., Ferris, L. A., Lydon, C., Nguyen, T., Jessop, N. A., Iafrate, A. J., Johnson, B. E., et al. (2019) · Clinical Cancer Research
Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment
Cited by 130
- Verified
Cetuximab response of lung cancer-derived EGF receptor mutants is associated with asymmetric dimerization
Cho, J., Chen, L., Sangji, N., Okabe, T., Yonesaka, K., Francis, J. M., Flavin, R. J., Johnson, W., Kwon, J., Yu, S., et al. (2013) · Cancer Research
Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research
Cited by 117
- Verified
Clinicopathologic and Genomic Factors Impacting Efficacy of First-Line Chemoimmunotherapy in Advanced NSCLC
Alessi, J. V., Elkrief, A., Ricciuti, B., Wang, X., Cortellini, A., Vaz, V. R., Lamberti, G., Frias, R. L., Venkatraman, D., Fulgenzi, C. A. M., et al. (2023) · Journal of Thoracic Oncology
Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations
Cited by 97
- Verified
Natural Language Processing to Ascertain Cancer Outcomes from Medical Oncologist Notes
Kehl, K. L., Xu, W., Lepisto, E., Elmarakeby, H., Hassett, M. J., Van Allen, E. M., Johnson, B. E., & Schrag, D. (2020) · JCO Clinical Cancer Informatics
Machine Learning in HealthcareBiomedical Text Mining and Ontologies
Cited by 90
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free